Transdermal patch for urinary incontinence

WatsonPharma, Inc. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.

J Urol. Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine vesus placebo in previously treated patients with urge and mixed urinary incontinence. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.

BJU Int. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial ACET. Curr Med Res Opin. Methodologic shortcomings inherent in a post-hoc analysis. Curr Urol Rep. Each update provides an independent review of a new medication by an author without financial association to the drug manufacturer. The series coordinator is Allen F. Shaughnessy, Pharm.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.

Contact afpserv aafp. Want to use this article elsewhere? Get Permissions. Read the Issue. Sign Up Now. Next: Whitish Papules and Plaques on the Tongue. Dec 15, Issue. Synopsis Oxytrol is a new transdermal patch form of the drug oxybutynin, which has long been used for urinary incontinence. Safety Oxtybutynin should not be used in patients with urinary retention, gastric retention, or uncontrolled angle-closure glaucoma.

Tolerability Dry mouth is the most common complaint with the oral anticholinergic drugs oxybutynin and tolterodine. Effectiveness Few studies have evaluated the effectiveness of transdermal oxybutynin. Simplicity The transdermal patch is applied to the abdomen, buttock, or hip, rotating sites every 3 to 4 days. Bottom Line The transdermal patch of oxybutynin is no more effective than the short- or long-acting oral form.

Read the full article. Get immediate access, anytime, anywhere. Choose a single article, issue, or full-access subscription. Results: The evaluated studies show that patients treated with OXY-TDS experience a significant reduction in urinary incontinence episodes compared with placebo, which is comparable to that observed in patients treated with oral oxybutynin or with tolterodine. In all of the studies, we observed improvements in symptoms from the second or third week of treatment and in a sustained manner until the end of treatment 6, 12 or 24 weeks.

The clinical practice study also showed improved quality of life, achieving benefits in numerous patient profiles, with an efficacy independent of previous treatments.

The safety of the drug was demonstrated in the various patient profiles. Conclusions: OXY-TDS represents an effective alternative for the symptomatic treatment of adult patients with OAB, which, thanks to its pharmacokinetic profile, better tolerability, different administration method and dosage, could represent an added value in treating special populations.

All rights reserved.